Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B
cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately …

The liver is an immunologically tolerant organ that is uniquely equipped to limit
hypersensitivity to food-derived antigens and bacterial products through the portal vein and …

More than 250 million people are living with chronic hepatitis B despite the availability of
highly effective vaccines and oral antivirals. Although innate and adaptive immune cells play …

Hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are responsible
for most cases of viral hepatitis. Infection by each type of virus results in a different typical …

BACKGROUND. The clinical management of chronic hepatitis B virus (HBV) patients is
based exclusively on virological parameters that cannot independently determine in which …

A great effort of research has been devoted in the last few years to develo** new anti-HBV
therapies of finite duration that also provide effective sustained control of virus replication …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …

Regulation of T cell responses by innate lymphoid cells (ILCs) is increasingly documented
and studied. Direct or indirect crosstalk between ILCs and T cells early during and after T …

Exhaustion of cytotoxic effector natural killer (NK) and CD8+ T cells have important functions
in the establishment of persistent viral infections, but how exhaustion is induced during …